Company intelligence / Profile preview
Beijing Biostar Pharmaceuticals Co., Ltd.
- Ownership
- Private
- Development stage
- Commercial
Overview
Utidelone injectable was approved in China in March 2021 as the first epothilone-based innovative anticancer drug for metastatic breast cancer. It has demonstrated superior efficacy and safety compared to standard regimens in Phase III trials. The oral capsule formulation of Utidelone has completed US Phase I recruitment with encouraging efficacy/safety data; pivotal studies are ongoing in China and the US. Multiple new indications and next-generation formulations are under clinical or preclinical development
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesAntibody-drug conjugates (ADC)Nano-formulations
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Beijing Biostar Pharmaceuticals Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Biostar Pharmaceuticals Co., Ltd..